Intra-Cellular Therapies, Inc.
ITCI
Peringkat dalam Saham
#1691
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Harga Saham
$131.87
Terakhir disinkronkan: 2025-04-02
Kapitalisasi Pasar
$12.68B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Intra-Cellular Therapies, Inc. (ITCI)
Kategori
Healthcare
Rasio P/B untuk Intra-Cellular Therapies, Inc. (ITCI)
Rasio P/B per October 2026 TTM: 11.84
Menurut laporan keuangan dan harga saham terbaru dari Intra-Cellular Therapies, Inc., rasio P/B saat ini (TTM) adalah 11.84. Pada akhir 2023, rasio P/B perusahaan adalah 11.61.
Riwayat rasio P/B untuk Intra-Cellular Therapies, Inc. dari 2013 hingga 2026
Rasio P/B pada akhir setiap tahun
| Tahun | Rasio P/B | Mengubah |
|---|---|---|
| 2026 (TTM) | 11.84 | 57.89% |
| 2024 | 7.50 | -35.41% |
| 2023 | 11.61 | 53.06% |
| 2022 | 7.59 | -25.46% |
| 2021 | 10.18 | 198.75% |
| 2020 | 3.41 | -64.92% |
| 2019 | 9.71 | 395.06% |
| 2018 | 1.96 | 33.29% |
| 2017 | 1.47 | -15.32% |
| 2016 | 1.74 | -57.28% |
| 2015 | 4.07 | -3.03% |
| 2014 | 4.19 | -48.67% |
| 2013 | 8.17 | 0.00% |
Rasio P/B untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/B | Perbedaan Rasio P/B | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -57.43% |
IN
|
